NCT03164616 2026-03-13
POSEIDON
AstraZeneca
Phase 3 Active not recruiting
Clinical Trials
11 trialsNCT04083235 2026-03-09
NAPOLI 3
Ipsen
Phase 3 Completed
NCT03976362 2026-02-25
KEYLYNK-008
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT03174275 2026-02-23
Carboplatin, Nab-Paclitaxel, Durvalumab Before Surgery and Adjuvant Therapy in Head and Neck Squamous Cell Carcinoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT02530489 2026-02-17
Nab-Paclitaxel and Atezolizumab Before Surgery in Treating Patients With Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04251533 2026-02-13
EPIK-B3
Novartis
Phase 3 Active not recruiting
NCT05226598 2026-02-05
MK-7684A-007
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT02999477 2026-01-29
A Study Of Changes In PD-L1 Expression During Preoperative Treatment With Nab-Paclitaxel And Pembrolizumab In Hormone Receptor-Positive Breast Cancer
Dana-Farber Cancer Institute
Phase 1 Completed
NCT04524702 2026-01-23
Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer
Emory University
Phase 2 Completed
NCT04770272 2026-01-12
neoMono
Palleos Healthcare GmbH
Phase 2 Terminated
NCT04148911 2025-12-26
EL1SSAR
Hoffmann-La Roche
Phase 3 Completed